JP2019535789A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535789A5 JP2019535789A5 JP2019528527A JP2019528527A JP2019535789A5 JP 2019535789 A5 JP2019535789 A5 JP 2019535789A5 JP 2019528527 A JP2019528527 A JP 2019528527A JP 2019528527 A JP2019528527 A JP 2019528527A JP 2019535789 A5 JP2019535789 A5 JP 2019535789A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- amino
- alkoxy
- hydroxy
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 1170
- 125000003545 alkoxy group Chemical group 0.000 claims description 402
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 214
- 125000003282 alkyl amino group Chemical group 0.000 claims description 208
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 204
- 125000000623 heterocyclic group Chemical group 0.000 claims description 90
- 239000002773 nucleotide Substances 0.000 claims description 79
- 125000003729 nucleotide group Chemical group 0.000 claims description 79
- 125000003118 aryl group Chemical group 0.000 claims description 60
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 60
- 229910052736 halogen Inorganic materials 0.000 claims description 60
- 150000002367 halogens Chemical class 0.000 claims description 60
- 125000001072 heteroaryl group Chemical group 0.000 claims description 60
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 58
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 54
- 125000001424 substituent group Chemical group 0.000 claims description 50
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 48
- 108020005067 RNA Splice Sites Proteins 0.000 claims description 40
- 108020004999 messenger RNA Proteins 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 35
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 30
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 30
- 229910052805 deuterium Inorganic materials 0.000 claims description 30
- 150000002431 hydrogen Chemical class 0.000 claims description 30
- 229910052739 hydrogen Inorganic materials 0.000 claims description 30
- 239000001257 hydrogen Substances 0.000 claims description 30
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical group NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 29
- 229930024421 Adenine Natural products 0.000 claims description 29
- 108700005078 Synthetic Genes Proteins 0.000 claims description 25
- 238000011144 upstream manufacturing Methods 0.000 claims description 22
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 20
- 125000005241 heteroarylamino group Chemical group 0.000 claims description 20
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 20
- 125000001475 halogen functional group Chemical group 0.000 claims description 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 15
- 229960000643 adenine Drugs 0.000 claims description 15
- 108700024394 Exon Proteins 0.000 claims description 12
- 108091027974 Mature messenger RNA Proteins 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 10
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 10
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 10
- 125000004414 alkyl thio group Chemical group 0.000 claims description 10
- 125000005100 aryl amino carbonyl group Chemical group 0.000 claims description 10
- 125000001769 aryl amino group Chemical group 0.000 claims description 10
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 10
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims description 10
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims description 10
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 10
- 125000004043 oxo group Chemical group O=* 0.000 claims description 10
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 9
- 108091092195 Intron Proteins 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 239000003607 modifier Substances 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 239000006166 lysate Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 239000013592 cell lysate Substances 0.000 claims description 2
- 125000000033 alkoxyamino group Chemical group 0.000 claims 36
- -1 amino, amino Chemical group 0.000 claims 12
- 125000006193 alkinyl group Chemical group 0.000 claims 6
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 6
- 239000013598 vector Substances 0.000 claims 3
- 239000013603 viral vector Substances 0.000 claims 2
- 241000710929 Alphavirus Species 0.000 claims 1
- 241000711404 Avian avulavirus 1 Species 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 108091034057 RNA (poly(A)) Proteins 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 230000001276 controlling effect Effects 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000005030 transcription termination Effects 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 description 16
- 125000000304 alkynyl group Chemical group 0.000 description 12
- 239000000126 substance Substances 0.000 description 8
- RODSCGMZJVUSFO-UHFFFAOYSA-N CC(C)N(C)C=C Chemical compound CC(C)N(C)C=C RODSCGMZJVUSFO-UHFFFAOYSA-N 0.000 description 1
- 0 CC1(C)*CCC1 Chemical compound CC1(C)*CCC1 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022108509A JP2022153413A (ja) | 2016-11-28 | 2022-07-05 | Ｒｎａスプライシングを調節する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662426619P | 2016-11-28 | 2016-11-28 | |
| US62/426,619 | 2016-11-28 | ||
| PCT/US2017/063323 WO2018098446A1 (en) | 2016-11-28 | 2017-11-27 | Methods for modulating rna splicing |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022108509A Division JP2022153413A (ja) | 2016-11-28 | 2022-07-05 | Ｒｎａスプライシングを調節する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019535789A JP2019535789A (ja) | 2019-12-12 |
| JP2019535789A5 true JP2019535789A5 (enExample) | 2021-06-17 |
Family
ID=62195368
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019528527A Pending JP2019535789A (ja) | 2016-11-28 | 2017-11-27 | Ｒｎａスプライシングを調節する方法 |
| JP2022108509A Pending JP2022153413A (ja) | 2016-11-28 | 2022-07-05 | Ｒｎａスプライシングを調節する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022108509A Pending JP2022153413A (ja) | 2016-11-28 | 2022-07-05 | Ｒｎａスプライシングを調節する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11702646B2 (enExample) |
| EP (1) | EP3544435A4 (enExample) |
| JP (2) | JP2019535789A (enExample) |
| CN (1) | CN110352007A (enExample) |
| AU (1) | AU2017363369A1 (enExample) |
| CA (1) | CA3043755A1 (enExample) |
| EA (1) | EA201991309A1 (enExample) |
| MX (1) | MX2019005588A (enExample) |
| WO (1) | WO2018098446A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3310169B1 (en) | 2015-05-30 | 2023-05-17 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
| AU2017363369A1 (en) | 2016-11-28 | 2019-05-30 | Ptc Therapeutics, Inc | Methods for modulating RNA splicing |
| US11608501B2 (en) | 2017-06-14 | 2023-03-21 | Ptc Therapeutics, Inc. | Methods for modifying RNA splicing |
| MX2020001425A (es) | 2017-08-04 | 2020-08-06 | Skyhawk Therapeutics Inc | Metodos y composiciones para modular el empalme. |
| US20210355509A1 (en) * | 2018-08-07 | 2021-11-18 | The Children's Hospital Of Philadelphia | Alternative splicing regulation of gene expression and therapeutic methods |
| CA3113817A1 (en) * | 2018-10-09 | 2020-04-16 | The University Of North Carolina At Chapel Hill | Regulated gene editing system |
| CN114007613A (zh) | 2019-02-05 | 2022-02-01 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| JP7603595B2 (ja) | 2019-02-06 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| US11129829B2 (en) | 2019-06-17 | 2021-09-28 | Skyhawk Therapeutics, Inc. | Methods for modulating splicing |
| EP4004213A1 (en) | 2019-07-25 | 2022-06-01 | Novartis AG | Regulatable expression systems |
| CN114746550A (zh) * | 2019-08-19 | 2022-07-12 | 斯托克制药公司 | 用于调节剪接和蛋白质表达的组合物和方法 |
| AU2020394867A1 (en) | 2019-12-02 | 2022-05-26 | Storm Therapeutics Limited | Polyheterocyclic compounds as METTL3 inhibitors |
| IL295542A (en) * | 2020-02-12 | 2022-10-01 | Childrens Hospital Philadelphia | Compositions and methods for inducible alternative splicing regulation of gene expression |
| CA3169676A1 (en) | 2020-02-28 | 2021-09-02 | Dominic Reynolds | Compounds and methods for modulating splicing |
| CN115551847A (zh) | 2020-02-28 | 2022-12-30 | 雷密克斯医疗公司 | 用于调节核酸剪接的哒嗪衍生物 |
| US20240226098A1 (en) | 2020-02-28 | 2024-07-11 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| AU2021228770A1 (en) | 2020-02-28 | 2022-09-29 | Remix Therapeutics Inc. | Thiophenyl derivatives useful for modulating nucleic acid splicing |
| MX2022012678A (es) | 2020-04-08 | 2023-01-11 | Remix Therapeutics Inc | Compuestos y metodos para modular el corte y empalme. |
| KR20230005210A (ko) | 2020-04-08 | 2023-01-09 | 레믹스 테라퓨틱스 인크. | 스플라이싱을 조절하기 위한 화합물 및 방법 |
| AU2021272972A1 (en) | 2020-05-13 | 2022-12-08 | Chdi Foundation, Inc. | HTT modulators for treating Huntington's disease |
| IL299543A (en) | 2020-07-02 | 2023-02-01 | Remix Therapeutics Inc | 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
| JP2023532331A (ja) | 2020-07-02 | 2023-07-27 | リミックス セラピューティクス インコーポレイテッド | 核酸をスプライシングするため及び増殖性疾患を処置するための修飾因子としての５－［５－（ピペリジン－４－イル）チエノ［３，２－ｃ］ピラゾール－２－イル］インダゾール誘導体及び関連する化合物並びにスプライシングを調節するための化合物及び方法 |
| WO2022214520A1 (en) * | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| CN116087519B (zh) * | 2021-05-17 | 2025-03-14 | 郑州大学第一附属医院 | 一种用于高危人群贲门腺癌早期筛查的标志物及其应用 |
| CN113604566B (zh) * | 2021-07-13 | 2023-05-16 | 中山大学孙逸仙纪念医院 | lncRNA BCYRN1在膀胱癌预后、治疗中的应用 |
| EP4395889A1 (en) | 2021-08-30 | 2024-07-10 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| WO2023034836A1 (en) | 2021-08-30 | 2023-03-09 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| US20240368163A1 (en) | 2021-08-30 | 2024-11-07 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| KR20240102938A (ko) | 2021-08-30 | 2024-07-03 | 레믹스 테라퓨틱스 인크. | 스플라이싱 조절을 위한 화합물 및 방법 |
| WO2023034812A1 (en) | 2021-08-30 | 2023-03-09 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| WO2023064879A1 (en) | 2021-10-13 | 2023-04-20 | Remix Therapeutics Inc. | Compounds and methods for modulating nucleic acid splicing |
| TW202333689A (zh) | 2021-10-13 | 2023-09-01 | 美商雷密克斯醫療公司 | 調節剪接之化合物及方法 |
| AU2022394333A1 (en) | 2021-11-17 | 2024-06-27 | Chdi Foundation, Inc. | HTT modulators for treating Huntington’s disease |
| WO2023133229A2 (en) | 2022-01-05 | 2023-07-13 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| US20250326748A1 (en) | 2022-01-05 | 2025-10-23 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| TW202337442A (zh) | 2022-01-05 | 2023-10-01 | 美商雷密克斯醫療公司 | 用於調節剪切之化合物及方法 |
| CN118647405A (zh) * | 2022-01-25 | 2024-09-13 | 上海魁特迪生物科技有限公司 | 改善认知障碍的方法 |
| EP4568962A2 (en) * | 2022-08-09 | 2025-06-18 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3558618A (en) | 1968-04-01 | 1971-01-26 | Dow Chemical Co | Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones |
| US4122274A (en) | 1977-05-25 | 1978-10-24 | Bristol-Myers Company | 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones |
| JPS56150091A (en) | 1980-03-28 | 1981-11-20 | Janssen Pharmaceutica Nv | 3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidine- 4-one derivative and its manufacture |
| US4342870A (en) | 1980-03-28 | 1982-08-03 | Janssen Pharmaceutica N.V. | Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives |
| US5089633A (en) | 1987-04-28 | 1992-02-18 | Georgia Tech Research Corporation | Substituted isocoumarins |
| US5726182A (en) | 1990-05-02 | 1998-03-10 | Abbott Laboratories | Quinolizinone type compounds |
| WO1993023398A1 (en) | 1992-05-13 | 1993-11-25 | E.I. Du Pont De Nemours And Company | Substituted pyrido[1,2-a]pyrimidinone derivatives as fungicides |
| CA2222322A1 (en) | 1995-06-06 | 1996-12-12 | Abbott Laboratories | Quinolizinone type compounds |
| US5869500A (en) | 1996-12-13 | 1999-02-09 | Hoffmann-La Roche Inc. | Pyridone compounds useful in treating Alzheimer's disease |
| WO2000017197A1 (en) | 1998-09-21 | 2000-03-30 | Biochem Pharma Inc. | Quinolizinones as integrin inhibitors |
| ATE312820T1 (de) | 1999-10-28 | 2005-12-15 | Trine Pharmaceuticals Inc | Pumpeninhibitoren zur freisetzung von medikamenten |
| DE60128655T2 (de) | 2000-01-24 | 2008-02-07 | Astrazeneca Ab | Durch einen morpholinrest substituierte therapeutische verbindungen |
| WO2002053576A1 (en) | 2001-01-05 | 2002-07-11 | The General Hospital Corporation | Viral delivery system for infectious transfer of large genomic dna inserts |
| CA2445697A1 (en) | 2001-04-26 | 2002-11-07 | Daiichi Pharmaceutical Co., Ltd. | Drug efflux pump inhibitor |
| MXPA04005510A (es) | 2001-12-07 | 2006-02-24 | Vertex Pharma | Compuestos basados en pirimidina utiles como inhibidores de gsk-3. |
| GB0205281D0 (en) | 2002-03-06 | 2002-04-17 | Novartis Ag | Organic compounds |
| ATE548354T1 (de) | 2002-07-24 | 2012-03-15 | Ptc Therapeutics Inc | Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen |
| US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
| AU2004249730A1 (en) | 2003-06-20 | 2004-12-29 | Novartis Vaccines And Diagnostics, Inc. | Pyridino(1,2-A)pyrimidin-4-one compounds as anticancer agents |
| DE602005002562T2 (de) | 2004-05-04 | 2008-01-31 | Warner-Lambert Company Llc | Pyrrolylsubstituierte pyridoä2,3-düpyrimidin-7-one und derivate davon als therapeutische mittel |
| US7399767B2 (en) | 2005-01-21 | 2008-07-15 | Ortho-Mcneil Pharmaceutical, Inc. | Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
| CN101213203A (zh) * | 2005-04-29 | 2008-07-02 | 教堂山北卡罗莱纳州大学 | 在转录后水平调节核酸表达的方法和组合物 |
| US7563601B1 (en) | 2005-06-01 | 2009-07-21 | City Of Hope | Artificial riboswitch for controlling pre-mRNA splicing |
| EP1910569A4 (en) * | 2005-06-17 | 2009-08-05 | Genizon Biosciences Inc | GENEMAP GENE CARD OF HUMAN GENES ASSOCIATED WITH LONGEVITY |
| CA2625262A1 (en) | 2005-10-13 | 2007-10-04 | Bc Cancer Agency | Modular genomes for synthetic biology and metabolic engineering |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| US8110681B2 (en) | 2006-03-17 | 2012-02-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compounds for the treatment of spinal muscular atrophy and other uses |
| US8337941B2 (en) | 2006-07-27 | 2012-12-25 | The Trustees Of Columbia University In The City Of New York | Fluorescent substrates for monoamine transporters as optical false neurotransmitters |
| WO2008077188A1 (en) | 2006-12-22 | 2008-07-03 | Avexa Limited | Bicyclic pyrimidinones and uses thereof |
| WO2009151546A2 (en) | 2008-05-27 | 2009-12-17 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| EP2138493A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidone derivatives |
| BRPI0913934A2 (pt) | 2008-07-02 | 2015-10-20 | Avexa Ltd | compostos tendo propriedades antivirais |
| WO2010019243A1 (en) | 2008-08-13 | 2010-02-18 | Ptc Therapeutics, Inc. | Methods for treating viral infections |
| WO2010083338A2 (en) | 2009-01-14 | 2010-07-22 | Philadelphia Health And Education Corporation | Modulation of pre-mrna using splice modulating oligonucleotides as therapeutic agents in the treatment of disease |
| US20100303776A1 (en) | 2009-04-16 | 2010-12-02 | The University Of North Carolina At Chapel Hill | Methods and compositions for regulated expression of multiple nucleic acids |
| WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
| US8754220B2 (en) | 2009-11-20 | 2014-06-17 | Merck Sharp & Dohme Corp. | Quinolizidinone carboxamide M1 receptor positive allosteric modulators |
| US20130012506A1 (en) | 2010-01-13 | 2013-01-10 | Zaesung No | Anti-infective pyrido (1,2-a) pyrimidines |
| EP3034078A1 (en) | 2010-09-27 | 2016-06-22 | Emergent Product Development Gaithersburg Inc. | 2-pyridone antimicrobial compositions |
| US9662314B2 (en) | 2011-10-21 | 2017-05-30 | Tufts Medical Center, Inc. | Compounds and methods for the treatment of muscular disease, and related screening methods |
| WO2013101974A1 (en) | 2011-12-30 | 2013-07-04 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| BR112014018027B1 (pt) | 2012-01-26 | 2020-10-27 | Ptc Therapeutics, Inc | composto, composição farmacêutica e usos dos mesmos e métodos para aumentar a inclusão de éxon 7 de ame2 em rnam que é transcrito a partir do gene ame2 e para aumentar a quantidade de proteína smn |
| EP2812004B1 (en) | 2012-02-10 | 2018-06-27 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| BR112014021531B1 (pt) | 2012-03-01 | 2022-10-04 | Ptc Therapeutics, Inc. | Composto, composição farmacêutica e usos dos mesmos |
| CN104470909B (zh) | 2012-03-23 | 2018-04-24 | Ptc医疗公司 | 用于治疗脊髓性肌萎缩的化合物 |
| WO2014012050A2 (en) | 2012-07-13 | 2014-01-16 | Indiana University Research & Technology Corporation | Compounds for treatment of spinal muscular atrophy |
| US9040712B2 (en) | 2013-01-23 | 2015-05-26 | Novartis Ag | Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions |
| MX372669B (es) | 2013-08-19 | 2020-04-23 | Hoffmann La Roche | Un compuesto que modifica el empalme del gen de foxm1 para usarse en la profilaxis o tratamiento de cáncer. |
| US10195202B2 (en) | 2013-12-19 | 2019-02-05 | Ptc Therapeutics, Inc. | Methods for modulating the amount of RNA transcripts |
| WO2015095449A1 (en) | 2013-12-19 | 2015-06-25 | Ptc Therapeutics, Inc. | Methods for modulating the amount rna transcripts |
| WO2015095446A1 (en) | 2013-12-19 | 2015-06-25 | Ptc Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
| HRP20230637T1 (hr) * | 2014-05-15 | 2023-09-29 | F. Hoffmann - La Roche Ag | Postupak za proizvodnju spojeva korisnih za liječenje spinalne mišićne atrofije |
| WO2016042015A1 (en) * | 2014-09-16 | 2016-03-24 | Centre National De La Recherche Scientifique (Cnrs) | Method for evaluating developmental competence of an oocyte |
| JP6884102B2 (ja) * | 2015-02-09 | 2021-06-09 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | がんの治療のための化合物 |
| EP3298017B1 (en) | 2015-05-20 | 2019-08-14 | H. Hoffnabb-La Roche Ag | Compounds for treating spinal muscular atrophy |
| EP3310169B1 (en) | 2015-05-30 | 2023-05-17 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
| AU2017363369A1 (en) | 2016-11-28 | 2019-05-30 | Ptc Therapeutics, Inc | Methods for modulating RNA splicing |
| US11608501B2 (en) | 2017-06-14 | 2023-03-21 | Ptc Therapeutics, Inc. | Methods for modifying RNA splicing |
| MX2020001425A (es) | 2017-08-04 | 2020-08-06 | Skyhawk Therapeutics Inc | Metodos y composiciones para modular el empalme. |
| KR20200057071A (ko) | 2017-09-25 | 2020-05-25 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱 조절제의 스크리닝 및 확인을 위한 방법 및 조성물 |
-
2017
- 2017-11-27 AU AU2017363369A patent/AU2017363369A1/en not_active Abandoned
- 2017-11-27 CA CA3043755A patent/CA3043755A1/en active Pending
- 2017-11-27 EP EP17873550.2A patent/EP3544435A4/en not_active Withdrawn
- 2017-11-27 CN CN201780084649.8A patent/CN110352007A/zh active Pending
- 2017-11-27 MX MX2019005588A patent/MX2019005588A/es unknown
- 2017-11-27 US US16/463,775 patent/US11702646B2/en active Active
- 2017-11-27 JP JP2019528527A patent/JP2019535789A/ja active Pending
- 2017-11-27 EA EA201991309A patent/EA201991309A1/ru unknown
- 2017-11-27 WO PCT/US2017/063323 patent/WO2018098446A1/en not_active Ceased
-
2022
- 2022-07-05 JP JP2022108509A patent/JP2022153413A/ja active Pending
-
2023
- 2023-05-12 US US18/316,871 patent/US20230272367A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535789A5 (enExample) | ||
| JP2022153413A5 (enExample) | ||
| JP6906591B2 (ja) | 筋特異的核酸調節エレメント並びにその方法及び使用 | |
| JP5823969B2 (ja) | 心臓特異的核酸調節因子ならびにこの方法および使用 | |
| JP2023093487A (ja) | 横隔膜特異的核酸調節エレメントならびにその方法および使用 | |
| JP2013509168A5 (enExample) | ||
| US10053709B2 (en) | Insulator to improve gene transfer vectors | |
| PT1501931E (pt) | Moléculas de arnnp (snrna) quiméricas portadoras de sequências anti-sentido contra as junções de splicing do gene da distrofina e suas aplicações terapêuticas | |
| JP2015517803A5 (enExample) | ||
| JP2020535845A5 (enExample) | ||
| Shih et al. | Exon-and contraction-dependent functions of titin in sarcomere assembly | |
| US10801027B2 (en) | Inhibitors of SRSF1 to treat neurodegenerative disorders | |
| WO2012049665A1 (en) | A modified human u1snrna molecule, a gene encoding for the modified human u1snrna molecule, an expression vector including the gene, and the use thereof in gene therapy | |
| Bassett et al. | Studies of the murine homolog of the multiple endocrine neoplasia type 1 (MEN1) gene, men1 | |
| WO2008101216A2 (en) | Gamma satellite insulator sequences and their use in preventing gene silencing | |
| Chang et al. | Structure and expression pattern of teleost caspase recruitment domain (CARD) containing proteins that are potentially involved in NF-κB signalling | |
| Beckmann et al. | Schistosoma mansoni: germ-line transformation approaches and actin-promoter analysis | |
| Rousset et al. | Optimizing synthetic miRNA minigene architecture for efficient miRNA hairpin concatenation and multi-target gene knockdown | |
| Herzfeld et al. | Structural and functional analysis of the human TAF1/DYT3 multiple transcript system | |
| Dormiani et al. | Long-term and efficient expression of human β-globin gene in a hematopoietic cell line using a new site-specific integrating non-viral system | |
| ES2991921T3 (es) | Terapias basadas en la telomerasa transcriptasa inversa | |
| Boonanuntanasarn et al. | Characterization and organization of the U6 snRNA gene in zebrafish and usage of their promoters to express short hairpin RNA | |
| WO2016104906A1 (ko) | 형질전환동물 제작을 위한 형질주입 시스템 | |
| JPWO2005063301A1 (ja) | Ｅｍｔ誘導剤 | |
| EP3898976A1 (en) | Synthetic microrna mimics |